123,447 Shares in Twist Bioscience Co. (NASDAQ:TWST) Purchased by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. purchased a new position in shares of Twist Bioscience Co. (NASDAQ:TWST) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 123,447 shares of the company’s stock, valued at approximately $4,550,000. Vestmark Advisory Solutions Inc. owned 0.21% of Twist Bioscience at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Twist Bioscience by 23.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,617 shares of the company’s stock valued at $316,000 after buying an additional 2,933 shares during the period. Strs Ohio boosted its position in Twist Bioscience by 6.5% in the 3rd quarter. Strs Ohio now owns 27,900 shares of the company’s stock valued at $565,000 after buying an additional 1,700 shares during the period. Rockland Trust Co. boosted its position in Twist Bioscience by 29.7% in the 3rd quarter. Rockland Trust Co. now owns 38,500 shares of the company’s stock valued at $780,000 after buying an additional 8,808 shares during the period. TD Asset Management Inc boosted its position in Twist Bioscience by 137.7% in the 3rd quarter. TD Asset Management Inc now owns 73,148 shares of the company’s stock valued at $1,482,000 after buying an additional 42,374 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its position in Twist Bioscience by 51.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock valued at $70,000 after buying an additional 1,179 shares during the period.

Twist Bioscience Stock Up 28.7 %

Shares of NASDAQ TWST traded up $9.20 during trading on Friday, hitting $41.21. The company had a trading volume of 4,458,430 shares, compared to its average volume of 909,964. The stock has a fifty day simple moving average of $34.03 and a two-hundred day simple moving average of $30.96. Twist Bioscience Co. has a fifty-two week low of $11.81 and a fifty-two week high of $43.21.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 30.81%. The business had revenue of $75.30 million for the quarter, compared to analyst estimates of $70.70 million. During the same quarter last year, the business earned ($1.06) earnings per share. The company’s revenue for the quarter was up 25.1% compared to the same quarter last year. Equities analysts predict that Twist Bioscience Co. will post -3.17 EPS for the current fiscal year.

Insider Transactions at Twist Bioscience

In other news, COO Patrick John Finn sold 2,174 shares of the firm’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $30.12, for a total value of $65,480.88. Following the transaction, the chief operating officer now directly owns 176,206 shares of the company’s stock, valued at $5,307,324.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Emily M. Leproust sold 1,128 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total value of $37,810.56. Following the transaction, the chief executive officer now directly owns 515,281 shares of the company’s stock, valued at $17,272,219.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Patrick John Finn sold 2,174 shares of the firm’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $30.12, for a total transaction of $65,480.88. Following the completion of the transaction, the chief operating officer now directly owns 176,206 shares in the company, valued at $5,307,324.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,211 shares of company stock valued at $449,573. Corporate insiders own 3.92% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Robert W. Baird upped their price target on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday. Barclays upped their price target on shares of Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a research report on Friday. The Goldman Sachs Group upgraded shares of Twist Bioscience from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Evercore ISI boosted their price objective on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, Scotiabank boosted their price objective on shares of Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a research note on Monday, February 5th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Twist Bioscience has an average rating of “Buy” and an average target price of $41.67.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.